Search Results - "GÜVEN, Deniz Can"

Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer by Yılmaz, Feride, Yaşar, Serkan, Tatar, Ömer Denizhan, Yıldırım, Hasan Çağrı, Güven, Deniz Can, Akyıldız, Arif, Chalabiyev, Elvin, Aktaş, Burak Yasin, Arık, Zafer, Erman, Mustafa

“…Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with…”
Get full text

Sonographic Measurements of Rectus Femoris Muscle Thickness Strongly Predict Neutropenia in Cancer Patients Receiving Chemotherapy by Güner, Gürkan, Özçakar, Levent, Baytar, Yusuf, Onur, Mehmet Ruhi, Demir, Metin, Aktaş, Burak Yasin, Aktepe, Oktay Halit, Güven, Deniz Can, Taban, Hakan, Yıldırım, Hasan Çağrı, Akın, Serkan, Aksoy, Sercan, Kara, Murat, Dizdar, Ömer

“…The objective of this study was to explore the possible association between low skeletal muscle mass (SMM)-assessed by computed tomography (CT) and ultrasound…”
Get full text

Assessment of abuse and related factors in older patients with cancer by Akagunduz, Baran, Altın, Zeynep, Atcı, Muhammed Mustafa, Ozer, Muhammet, Güven, Deniz Can, Çil, İbrahim, Özçiçek, Fatih, Demirtaş, Levent, Duzgun, Eren, Gunderci, Azad, Arslan, Yusuf

“…Background Older cancer patients are more likely to present with functional dependency, multiple comorbidities, polypharmacy, malnutrition, and cognitive…”
Get full text

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study by Yıldırım, Hasan Çağrı, Mutlu, Emel, Chalabiyev, Elvin, Özen, Miraç, Keskinkılıç, Merve, Ön, Sercan, Çelebi, Abdussamet, Dursun, Bengü, Acar, Ömer, Kahraman, Seda, Aykan, Musa Barış, Kaman, Ömür, Doğan, Akif, Erdoğan, Atike Pınar, Melisa Celayir, Özde, Günenç, Damla, Güven, Deniz Can, Vedat Bayoğlu, İbrahim, Yavuzşen, Tuğba, Hacıbekiroğlu, İlhan, İnanç, Mevlüde, Kılıçkap, Saadettin, Yalçın, Şuayib, Aksoy, Sercan

“…Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors,…”
Get full text

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study by Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Açıkgöz, Özgür, Sezer, Ahmet, Gürbüz, Mustafa, Ak, Naziye, Yücel, Şebnem, Ayhan, Murat, Erol, Cihan, Demirkıran, Aykut, Mandel, Nil Molinas, Shbair, Abdallah, Gökmen, İvo, Başoğlu, Tuğba, Paydaş, Semra, Demiray, Atike Gökçen, İriağaç, Yakup, Şakalar, Teoman, Zeynelgil, Esra, Tatlı, Ali Murat, Bahçeci, Aykut, Güven, Deniz Can, Caner, Burcu, Can, Alper, Gülmez, Ahmet, Karakaş, Yusuf, Yalçın, Bülent, Demirkazık, Ahmet, Bilici, Ahmet, Aydıner, Adnan, Yumuk, Perran Fulden, Şendur, Mehmet Ali Nahit

“…Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients…”
Get full text

Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study by Ünal, Çağlar, Ordu, Çetin, Özmen, Tolga, İlgun, Ahmet Serkan, Çelebi, Filiz, Baysal, Bülent, Özkurt, Enver, Duymaz, Tomris, Erdoğan İyigün, Zeynep, Kurt, Sevgi, Öztürk, Mehmet Alper, Pilancı, Kezban Nur, Alço, Gül, Yararbaş, Kanay, Kayan Tapan, Tuba, Güven, Deniz Can, Soybir, Gürsel, Özmen, Vahit

“…Estradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in…”
Get full text

Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia by Aktaş, Burak Yasin, Ata, Emine Büşra, Çeşmeci, Engin, Çakır, İbrahim Yahya, Coşkunpınar, Muharrem, Tahillioğlu, Yağmur, Güner, Gürkan, Güven, Deniz Can, Arık, Zafer, Kertmen, Neyran, Dizdar, Ömer, Yalçın, Şuayib, Aksoy, Sercan

“…Anemia remains an essential concern affecting the quality of life and the survival of cancer patients. Although there are different approaches to treating…”
Get full text

Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia by Bilgin, Emre, Dizdar, Ömer, Güven, Deniz Can, Ceylan, Serdar, Aybi, Özge, Fırlatan, Büşra, Kardaş, Rıza Can, Yıldırım, Tolga, Hayran, Mutlu Kadir, Kalyoncu, Umut, Özen, Seza

“…Although chronic inflammation has been associated with increased cancer risk in various disease including hepatitis or inflammatory bowel disease, a lower…”
Get full text

Worse patient–physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG) by Alkan, Ali, Yaşar, Arzu, Güç, Zeynep Gülsüm, Gürbüz, Mustafa, Başoğlu, Tuğba, Sezgin Göksu, Sema, Buğdaycı Başal, Fatma, Türk, Hacı Mehmet, Özdemir, Özlem, Yeşil Çınkır, Havva, Güven, Deniz Can, Kuş, Tülay, Türker, Sema, Koral, Lokman, Karakaş, Yusuf, Ak, Naziye, Paydaş, Semra, Karcı, Ebru, Demiray, Atike Gökçen, Demir, Atakan, Alan, Özkan, Keskin, Özge, Nayır, Erdinç, Tanrıverdi, Özgür, Yavuzşen, Tuğba, Yumuk, Perran Fulden, Ateş, Öztürk, Coşkun, Hasan Şenol, Turhal, Serdar, Çay Şenler, Filiz

“…Objective Fear of cancer recurrence (FCR) is an important psychological trauma associated with reduction in the quality of life, disruptions in the level of…”
Get full text

Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma by Aktepe, Oktay Halit, Guner, Gurkan, Guven, Deniz Can, Taban, Hakan, Yildirim, Hasan Cagri, Sahin, Taha Koray, Ardic, Fadime Sinem, Yeter, Haci Hasan, Yuce, Deniz, Erman, Mustafa

Get full text

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review by Güven, Deniz Can, Thong, Melissa Sy, Arndt, Volker

“…Immune checkpoint inhibitors (ICIs) have become a central part of cancer care. However, the survivorship outcomes in patients treated with ICIs are…”
Get full text

Fusobacterium and colorectal carcinogenesis by Güven, Deniz Can, Dizdar, Omer

Get full text

HER2-low breast cancer could be associated with an increased risk of brain metastasis by Guven, Deniz Can, Kaya, Mehmet Burak, Fedai, Burak, Ozden, Mucahit, Yildirim, Hasan Cagri, Kosemehmetoglu, Kemal, Kertmen, Neyran, Dizdar, Omer, Uner, Aysegul, Aksoy, Sercan

“…Purpose The HER2-low breast cancer is a newly recognized entity with the clinical characteristics is yet to be defined. We hypothesized that HER2-low breast…”
Get full text

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group by Ünal, Çağlar, Azizy, Abdulmunir, Karabulut, Senem, Taştekin, Didem, Akyıldız, Arif, Yaşar, Serkan, Yalçın, Şuayib, Çoban, Eyüp, Evrensel, Türkkan, Kalkan, Ziya, Oruç, Zeynep, Derin, Sümeyra, Turna, Zeynep Hande, Bayram, Doğan, Köş, Fahriye Tuğba, Şendur, Mehmet Ali Nihat, Sever, Nadiye, Ercelep, Özlem, Seyyar, Mustafa, Kefeli, Umut, Uygun, Kazım, Özçelik, Melike, Ön, Sercan, Şanlı, Ulus Ali, Canaslan, Kübra, Ünek, İlkay Tuba, Yücel, Kadriye Bir, Özdemir, Nuriye, Yazıcı, Ozan, Güzel, Halil Göksel, Salim, Derya Kıvrak, Göksu, Sema Sezgin, Tatlı, Ali Murat, Ordu, Çetin, Selvi, Oğuzhan, Sakin, Abdullah, Büyükbayram, Mehmet Emin, Dursun, Bengü, Ürün, Yüksel, Arak, Hacı, Ağdaş, Gözde, Uğraklı, Muzaffer, Hendem, Engin, Eryılmaz, Melek Karakurt, Bilgin, Burak, Topçu, Atakan, Şimşek, Melih, Büyükşimşek, Mahmut, Akay, Büşra, Erdal, Gülçin Şahingöz, Karataş, Fatih, Alan, Özkan, Çağlayan, Melek, Kahvecioğlu, Fatma Akdağ, Demirci, Ayşe, Paksoy, Nail, Çetin, Bülent, Gümüş, Mahmut, Ak, Naziye, Aydınalp, Yasemin, Paydaş, Semra, Güven, Deniz Can, Kılıçkap, Saadettin, Sağlam, Sezer

“…Abstract Introduction This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in…”
Get full text

Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer by Şener, Görkem Yazıcı, Sütcüoğlu, Osman, Öğüt, Betül, Güven, Deniz Can, Kavuncuoğlu, Altan, Özdemir, Nuriye, Özet, Ahmet, Aksoy, Sercan, Tezel, Yeşim Gaye Güler, Akyürek, Nalan, Yazıcı, Ozan

“…Background PD-L1 and VISTA are thought to play a role in escape from the immune system, tumor progression, and treatment response in tumoral tissue. The…”
Get full text

Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment by Gürler, Fatih, İlhan, Ayşegül, Güven, Deniz Can, Turhan, Okan, Kurt İnci, Bediz, Sütçüoğlu, Osman, Yildiz, Fatih, Arik, Zafer, Öksüzoğlu, Berna, Yalçin, Şuayib, Özdemir, Nuriye, Yazici, Ozan, Özet, Ahmet

“…We aimed to compare the efficacy and the safety of the FOLFOX and the FLOT regimens in metastatic gastric cancer (mGC) as first-line treatment. It was a…”
Get full text

SMART syndrome: a case report by Bozkurt, Saliha, Toprak, Berna, Yıldırım, Hasan Çağrı, Parlak, Şafak, Güven, Deniz Can, Kertmen, Neyran, Oğuz, Kader Karlı, Dizdar, Ömer

“…Introduction Stroke-like migraine attacks after radiation therapy (SMART) syndrome, is a late complication of brain radiotherapy (1). Symptoms are commonly…”
Get full text

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group by Gürbüz, Mustafa, Kiliçkap, Saadettin, Bilici, Ahmet, Karadurmuş, Nuri, Sezer, Ahmet, Şendur, Mehmet Ali Nahit, Paydaş, Semra, Artaç, Mehmet, Fulden Yumuk, Perran, Gürsoy, Pinar, Uysal, Mükremin, Şenol Coşkun, Hasan, Tatli, Ali Murat, Selçukbiricik, Fatih, Dişel, Umut, Köksoy, Elif Berna, Güven, Deniz Can, Uğrakli, Muzaffer, Akkuş, Erman, Yücel, Şebnem, Erol, Cihan, Karakaya, Serdar, Şakalar, Teoman, Khanmammadov, Nijat, Paksoy, Nail, Demirkazik, Ahmet

“…Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although…”
Get full text

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study) by Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Atcı, Muhammed Mustafa, Kahraman, Seda, Kılıçkap, Saadettin, Güven, Deniz Can, Keskinkılıç, Merve, Ayhan, Murat, Eren, Önder, Mustafayev, Fatma Nihan Akkoç, Yaman, Şebnem, Bayram, Ertuğrul, Ertürk, İsmail, Özcan, Erkan, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, Baytemür, Naziyet Köse, Gülmez, Ahmet, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Tatlı, Ali Murat, Ergün, Yakup, Ak, Naziye, Ünal, Çağlar, Özgün, Mehmet Alpaslan, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, Şendur, Mehmet Ali Nahit

“…Introduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced…”
Get full text

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group by Gürbüz, Mustafa, Kutlu, Yasin, Akkuş, Erman, Köksoy, Elif Berna, Köse, Naziyet, Öven, Bala Başak, Uluç, Başak Oyan, Demiray, Atike Gökçen, Erdem, Dilek, Demir, Bilgin, Turhal, Nazım Serdar, Üskent, Necdet, Akbaş, Sinem, Selçukbiricik, Fatih, İnal, Ali, Bilici, Ahmet, Ölmez, Ömer Fatih, Çabuk, Devrim, Ünal, Çağlar, Hızal, Mutlu, Şendur, Mehmet Ali Nahit, Korkmaz, Mustafa, Karadurmuş, Nuri, Ertürk, İsmail, Göksu, Sema Sezgin, Tatlı, Ali Murat, Güven, Deniz Can, Kılıçkap, Saadettin, Paksoy, Nail, Aydıner, Adnan, Çınkır, Havva Yeşil, Özkul, Özlem, Öztürk, Akın, Ballı, Sevinç, Kemal, Yasemin, Erdoğan, Atike Pınar, Er, Özlem, Yumuk, Perran Fulden, Demirkazık, Ahmet

“…Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC)…”
Get full text